Skip to content

Potential Pulmonary Benefit of Low Pressure Laparoscopic Cholecystectomy in Selected Patients

The Pulmonary Effects of Low Pressure Versus Standard Pressure Laparoscopic Cholecystectomy in Patients With Cardiopulmonary Disorders: A Prospective Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04670952
Acronym
POPLOP
Enrollment
140
Registered
2020-12-17
Start date
2019-06-10
Completion date
2021-12-31
Last updated
2020-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis/Cholelithiasis, Cholecystitis; Gallstone, Polyp Gallbladder

Keywords

low pressure; laparoscopic cholecystectomy

Brief summary

Standard Pressure Laparoscopic Cholecystectomy,as the standard for cholecystectomy, can lead to about 15% of pulmonary atelectasis. According to literature, low pressure laparoscopic cholecystectomy is thought to probably decrease cardio-pulmonary related complications and postoperative pain. However, the previous studies have presented controversial results. Our study aim to evaluate the potential pulmonary benefit of low pressure laparoscopic cholecystectomy in elderly or patients accompanied with cardio-pulmonary disorders.

Detailed description

Standard Pressure Laparoscopic Cholecystectomy, SPLC;12-16mmHg,as the standard for cholecystectomy, can lead to about 15% of pulmonary atelectasis. According to literature, Low Pressure Laparoscopic Cholecystectomy, LPLC;8-10mmHg is thought to probably decrease cardio-pulmonary related complications and postoperative pain. However, most of the existing study have combined population with all age scale, bringing bias to the result. Our study aim to evaluate the potential pulmonary benefit of low pressure laparoscopic cholecystectomy in elderly or patients accompanied with cardio-pulmonary disorders.

Interventions

OTHERLow Pressure Laparoscopic Cholecystectomy

Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.

OTHERStandard Pressure Laparoscopic Cholecystectomy

Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

It will be single blinded. Operator, first assistant and data collector could not be blinded. Whereas patients, nurses, data analyzer, and those who have the access to the primary predictor will be blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 18-85; 2. Patients receiving laparoscopic cholecystectomy due to benign gallbladder diseases; 3. Older patient or accompanied by cardiopulmonary diseases (age\>60 years, hypertension, Diabetes Mellitus, coronary heart disease, arrhythmia, chronic bronchitis, emphysema, history of heart surgery, history of lung surgery, history of mediastinal surgery, asthma, et al); 4. Aged older than 60, with or without the above diseases; 5. American society of Aneshesiologists (ASA) II or higher; 6. Informed consent acquired.

Exclusion criteria

1. Having contraindication of laparoscopic operations; 2. History at epigastric surgery. -

Design outcomes

Primary

MeasureTime frameDescription
Change of partial pressure of carbon dioxide(pCO2)Within postoperative 30 days.Change of pCO2 in arterial blood gas test

Secondary

MeasureTime frameDescription
operation timeDuring surgery.skin to skin operative duration
conversion rate to open surgeryDuring surgery.Need of conversion to open surgery duo to adhesion, hemorrhage, or other reasons.
visual analogue scale (VAS)During postoperative 24 hours.For evaluation of postoperative pain degree, using VAS, scoring 1-10 scores.
complication rateWithin postoperative 30 days.Rate of total postoperative complications

Countries

China

Contacts

Primary ContactFeng Tian, Doctor
andytianfeng@126.com+86-01069152600
Backup ContactJun Lu, Doctor
pumchtf@sina.com+86-01069152601

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026